GILD250103P91000
- 0.01
- 0.000.00%
Gilead Sciences Newsroom
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
CES Tech Conference Week Starts with Nvidia and Chips Climbing | Live Stock
Citi's Themes: Top Stocks in AI, Leisure, Fin-tech, Video Gaming, Etc. Vs. Their SA Quant Ratings
Gilead Sciences, Inc. (GILD): A Bull Case Theory
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Gilead Buys $20.1 Million of Assembly Biosciences Stock -- Barron's
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Santa Claus Came Without Rallying the Troops | Live Stock
Gilead (GILD.US) has received approval for the long-acting HIV treatment "Lenacapavir" to be marketed in China.
The official NMPA website shows that Gilead's (GILD.US) HIV therapy, Lenacapavir tablets and Lenacapavir injection, has received marketing approval.
Is Gilead Sciences, Inc. (GILD) the Best Pharma Dividend Stocks to Buy In 2024?
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
Morgan Stanley: Personalized cancer vaccines and ADCs will become the main catalysts in the oncology treatment Industry by 2025.
Morgan Stanley stated in a recent research report that personalized cancer vaccines and antibody-drug conjugates (ADCs) will become one of the major innovations in cancer biotechnology next year.
Gilead Buys $20.1 Million of Assembly Biosciences Stock -- Barrons.com
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Weekly Buzz: So far, Santa is Letting us Down